Cigna executive trades stock and receives awards

Cigna Group executive Neville Everett reported several equity transactions involving company stock.

Rhea-AI Filing Summary

Cigna Group executive Neville Everett reported several equity transactions involving company stock. On March 2, he completed an open-market sale of 1,719 common shares at a price of $288.91 per share under a pre-arranged Rule 10b5-1 trading plan adopted on May 22, 2025.

On February 27, he received equity awards tied to company performance and compensation programs, including 2,602 and 2,678 common shares granted at no cost and 4,127 employee stock options that vest in three equal annual installments beginning March 1, 2027. Some common shares (883 and 517) were withheld to cover tax obligations upon settlement of strategic performance shares and vesting of restricted shares.

Insider Trade Summary

Net Seller: 1,719 shares

Net Sell 6 txns

Insider Neville Everett

Role See Remarks

Sold 1,719 shs ($497K)

Type	Security	Shares	Price	Value
Sale	Common Stock, $.01 Par Value	1,719	$288.91	$497K
Grant/Award	Employee Stock Option (Right to Buy)	4,127	$0.00	$0.00
Grant/Award	Common Stock, $.01 Par Value	2,602	$0.00	$0.00
Grant/Award	Common Stock, $.01 Par Value	2,678	$0.00	$0.00
Exercise Price or Tax Liability	Common Stock, $.01 Par Value	883	$287.55	$254K
Exercise Price or Tax Liability	Common Stock, $.01 Par Value	517	$287.55	$149K

Holdings After Transaction: Employee Stock Option (Right to Buy) — 4,127 contracts (Direct); Common Stock, $.01 Par Value — 5,670 shares (Direct)

Footnotes (6)

1. F1. The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals.
2. F2. These restricted shares vest in three equal annual installments beginning March 1, 2027.
3. F3. Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares.
4. F4. Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.
5. F5. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2025.
6. F6. This option vests in three equal annual installments beginning March 1, 2027.

FAQ

What insider transactions did Neville Everett report at Cigna Group (CI)?

Neville Everett reported an open-market sale of 1,719 Cigna Group common shares and several equity awards, including restricted stock and employee stock options. Some shares were also withheld to satisfy tax obligations related to performance-based and restricted share settlements.

How many Cigna Group (CI) shares did Neville Everett sell and at what price?

Neville Everett sold 1,719 Cigna Group common shares in an open-market transaction at a price of $288.91 per share. The sale was executed as part of a pre-arranged Rule 10b5-1 trading plan he adopted on May 22, 2025.

What stock awards did Neville Everett receive from Cigna Group (CI)?

Neville Everett received 2,602 and 2,678 Cigna Group common shares as equity awards at no cost, plus 4,127 employee stock options. These awards relate to performance periods and compensation programs and include vesting schedules beginning March 1, 2027 for the options.

Were any of Neville Everett’s Cigna Group (CI) transactions related to taxes?

Yes. Cigna Group withheld 883 and 517 common shares from Neville Everett to satisfy tax obligations. These withholdings occurred upon settlement of strategic performance shares and upon vesting of restricted shares, rather than through open-market sales for cash.

What is the vesting schedule for Neville Everett’s new Cigna (CI) equity awards?

Neville Everett’s newly granted employee stock options vest in three equal annual installments beginning March 1, 2027. Certain restricted share awards are also scheduled to vest in three equal annual installments starting the same date, aligning with Cigna’s long-term incentive structure.

Were Neville Everett’s Cigna Group (CI) share sales pre-planned?

The 1,719-share sale by Neville Everett was executed under a Rule 10b5-1 trading plan he adopted on May 22, 2025. Such plans allow insiders to pre-schedule trades, helping separate personal trading decisions from the timing of material nonpublic information.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 03/03/2026 - 07:18 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

X

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Neville Everett

(Last) (First) (Middle)

900 COTTAGE GROVE RD

(Street)

BLOOMFIELD CT 06002

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cigna Group [ CI ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	See Remarks

3. Date of Earliest Transaction (Month/Day/Year)
02/27/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock, $.01 Par Value	02/27/2026		A		2,602(1)	A	$0	6,111	D
Common Stock, $.01 Par Value	02/27/2026		A		2,678(2)	A	$0	8,789	D
Common Stock, $.01 Par Value	02/27/2026		F		883(3)	D	$287.55	7,906	D
Common Stock, $.01 Par Value	02/27/2026		F		517(4)	D	$287.55	7,389	D
Common Stock, $.01 Par Value	03/02/2026		S(5)		1,719	D	$288.91	5,670	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Employee Stock Option (Right to Buy)	$287.5475	02/27/2026		A		4,127		03/01/2027(6)	02/27/2036	Common Stock, $.01 Par Value	4,127	$0	4,127	D

Explanation of Responses:

1. The reported securities are shares of common stock received pursuant to the settlement of strategic performance shares for the 2023-2025 three-year performance period. The number of shares of common stock received was based upon actual performance against pre-established Company performance goals.

2. These restricted shares vest in three equal annual installments beginning March 1, 2027.

3. Represents shares withheld to satisfy tax obligations upon settlement of strategic performance shares.

4. Represents shares withheld to satisfy tax obligations upon vesting of restricted shares.

5. This transaction was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on May 22, 2025.

6. This option vests in three equal annual installments beginning March 1, 2027.

Remarks:

	Tyler Gratton, attorney-in-fact	03/02/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.